Turns waste water from oil wells into pharmaceutical-grade iodine using a proprietary polymer technology.
At a glance
- Depends onDownstream position: depends on 10 industries, supplies 5
- ScaleMarket cap is in the bottom 5% globally
Turns waste water from oil wells into pharmaceutical-grade iodine using a proprietary polymer technology.
What this company is and how it runs — written from structure, not news.
Iofina takes the brine water that oil and gas drillers in Oklahoma, Montana, and North Dakota pump out of the ground as waste, runs it through its WET IOsorb polymer before the dissolved iodine disperses, and sells the extracted iodine as pharmaceutical-grade crystals. Because iodine concentration drops the further the brine travels from the wellhead, each processing unit has to be built at the drill site itself, which means entering a new basin requires negotiating brine supply agreements with individual operators, obtaining EPA permits in that jurisdiction, and constructing on-site infrastructure — none of which can be shared with existing facilities. Once a site clears the 12 to 18 months of qualification testing that pharmaceutical customers must complete before approving any new iodine supplier, those customers have little reason to restart that process with a competitor, so the facilities that have already passed qualification tend to stay qualified. The single thread the whole business hangs on is active drilling: if crude oil prices fall far enough that regional operators slow down, brine volumes shrink, iodine output falls, and the wellhead equipment goes idle — because the WET IOsorb polymer is matched to oil-field brine chemistry and cannot simply be pointed at Chilean caliche deposits, where most of the world's iodine otherwise comes from.
How does this company make money?
The company sells pharmaceutical-grade iodine crystals and iodine derivative compounds by the pound. Those sales happen under long-term supply contracts with pharmaceutical and industrial customers, and the price per pound is typically tied to global iodine market rates.
What makes this company hard to replace?
Pharmaceutical customers must run 12 to 18 months of qualification testing on any new iodine supplier before they are allowed to use that supplier's product under USP purity standards. That alone makes switching slow and expensive. The processing facilities are also physically fixed at specific oil field locations and cannot be moved, so if a customer needs continuous supply, they are tied to those specific sites. If a different supplier uses a different purification method, the customer must go through a full revalidation process before they can approve that supplier's iodine for use.
What limits this company?
The company can only extract as much iodine as the drilling operators upstream of it are producing in brine. If a drilling operator slows down or shuts in wells, brine volume at that wellhead drops and iodine output drops with it. Spreading agreements across multiple operators in Oklahoma, Montana, and North Dakota reduces the risk from any single operator, but a broad slowdown in U.S. drilling activity — such as one caused by falling crude oil prices — shrinks brine supply across all of those agreements at the same time.
What does this company depend on?
The company cannot operate without produced brine water from oil and gas drilling operators in its target basins. It also depends on its proprietary WET IOsorb polymer technology to extract the iodine, pharmaceutical-grade processing equipment certified for iodine handling, transportation infrastructure capable of moving hazardous chemicals, and EPA permits for brine water processing in each state where it operates.
Who depends on this company?
Pharmaceutical manufacturers that produce contrast agents for medical imaging depend on this company's iodine for iodinated contrast media — a shortage would directly affect the supply of those imaging products. Industrial catalyst producers rely on iodine compounds from this supply for specific chemical synthesis processes. Veterinary pharmaceutical companies use iodine in antiseptics and feed supplements, and a disruption here would affect those products as well.
How does this company scale?
The WET IOsorb extraction technology itself is relatively cheap to replicate once it has been developed — deploying it at an additional oil field does not require reinventing the chemistry. What does not get cheaper with growth is everything else: each new basin requires its own brine supply agreements negotiated with individual drilling operators, its own EPA permits in that jurisdiction, and its own on-site processing infrastructure built at the wellhead. None of that can be centralized or shared across locations.
What external forces can significantly affect this company?
Global crude oil prices are the most direct outside force — when oil prices fall, drilling slows, brine output drops, and the company's feedstock shrinks. Environmental regulations aimed at hydraulic fracturing or produced water disposal in Oklahoma, Montana, or North Dakota could cut off access to brine sources entirely, regardless of oil prices. On the demand side, disruptions to Chilean iodine mining — which supplies most of the world's iodine — affect global iodine prices and can increase demand for this company's North American alternative.
Where is this company structurally vulnerable?
If U.S. oil and gas drilling activity fell sharply — because crude oil prices collapsed for an extended period, or because regulations restricted hydraulic fracturing or produced water discharge in Oklahoma, Montana, or North Dakota — brine volumes at the wellheads would fall below the level needed to keep the processing facilities running economically. The WET IOsorb technology cannot be packed up and redeployed to Chilean caliche mines or any other iodine source, so idle wellhead equipment would simply stay idle.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three present-state observations co-occur: latest-year OCF/Net Income elevated, revenue growth composite (median × positive-year share × stability) elevated, and trailing OCF margin elevated. The configuration describes cash backing of earnings, multi-year growth consistency, and elevated cash-margin level — without claiming a causal compounding mechanism between them.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
Follow hydrocarbons through cracking, separation, polymers, conversion, use, and recovery. A cracker produces a coupled slate, so feedstock, product demand, contracts, plant configuration, and waste routes constrain one another.
Follow feedstock through monomer and polymer production, compounding, conversion, packaging, use, collection, recycling, combustion, and disposal. Resin tonnes and recycling rates are bounded measurements, not proof that the original function returned.
Follow natural rubber from tree and tapping through coagulation, grading, compounding, vulcanization, service, and recovery. The chain preserves some properties while closing others, and money arrives on a faster clock than a new stand of trees.
CompanyGraph